HIV / AIDS
Gilead Starts Phase 2 Trial of Tenofovir Pro-drug GS-7340
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 27 January 2012 00:00
Gilead Sciences this week announced the start of a new Phase 2 clinical trial that will compare an all-in-1 combination pill containing GS-7340 -- a pro-drug of tenofovir (Viread, also in the Truvada and Atripla coformulations) that can be taken in lower doses -- versus the experimental Quad combo containing the same drugs with tenofovir itself.
Pets and Parenthood Help Women Cope with HIV
- Details
- Category: Women & HIV
- Published on Friday, 27 January 2012 00:00
Identification with their role as a mother, grandmother, or pet owner helped women with HIV cope with having a chronic disease, according to a study published in the January 2012 online edition of Women's Health Issues.
FDA Approves New Tenofovir (Viread) Formulation and Dosing Regimen for HIV+ Children
- Details
- Category: HIV Treatment
- Published on Tuesday, 24 January 2012 00:00
The U.S. Food and Drug Administration (FDA) and Gilead Sciences last week announced the approval of a new oral powder formulation and new strength tablets of tenofovir (brand name Viread) -- one of the most widely used nucleoside reverse transcriptase inhibitors (NRTIs) in combination antiretroviral regimens -- as well as new dosing recommendations for HIV positive children and adolescents age 2 through 18 years.
Nevirapine for 6 Months during Breast-feeding Prevents Perinatal HIV Transmission
- Details
- Category: Pregnancy & HIV MTCT
- Published on Tuesday, 24 January 2012 00:00
Treating babies with nevirapine (Viramune) for 6 months while breast-feeding significantly reduced the risk of mother-to-child HIV transmission, though it did not alter the likelihood of infant mortality, according to a study of HIV positive African women and their babies described in the January 21, 2012, issue of The Lancet.
Oral HIV Tests May Be Less Accurate than Blood Tests
- Details
- Category: HIV Testing & Diagnosis
- Published on Tuesday, 24 January 2012 00:00
Oral HIV antibody testing is quick and convenient, but this method is not quite as accurate as blood testing in low-prevalence settings, being more likely to produce false-positive results, according to a study review and meta-analysis described in the January 24, 2012, online edition of The Lancet Infectious Diseases.
UPCOMING 1/25/12: Administration on Aging 'Graying of HIV/AIDS' Webinar
- Details
- Category: HIV & Aging
- Published on Tuesday, 24 January 2012 00:00
The U.S. Administration on Aging (AoA) will host a free webinar entitled “The Graying of HIV/AIDS: Community Resources for the Aging Services Network” on Wednesday, January 25, from 2:00 to 3:00 pm Eastern Standard Time.
Low but Detectable Viral Load Can Lead to HIV Rebound
- Details
- Category: HIV Disease Progression
- Published on Tuesday, 24 January 2012 00:00
People with HIV RNA levels < 50 copies/mL but detectable may still experience viral rebound while on antiretroviral therapy, and should consider switching to a more effective regimen if low-level viral load persists, according to a study described in the January 11, 2012, advance online edition of Clinical Infectious Diseases.
More Articles...
- Vitamin D May Improve Bone Health in Young HIV+ People Taking Tenofovir
- HIV Cure Working Group Calls for Abstracts for July Symposium
- Sangamo HIV Gene Therapy Trials: Until There's A Functional Cure, Treatment!
- HIV Viral Load Predicts Risk of Infection in Large Study
- Electrocautery Prevents Progression to Anal Cancer in HIV Positive and Negative Gay Men
Web Design and Development by